EU General Court upholds the European Commission’s decision in Perindopril litigation

Deepthi | Myequity news | Date : 12-12-2018 19:10:00 IST

The General Court of the European Union has delivered its judgment concerning Lupin's and other companies appeal against the European Commission's (EC) 2014 decision in the Perindopril litigation. The General Court upheld the EC’s decision holding Lupin liable to pay a fine of EUR 40 million. Lupin is evaluating further course of action.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti- TB segment.


More from Myequity